Company Description
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets.
The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease.
It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression.
The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2).
The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025.
The company was founded in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| Industry | Computer Hardware |
| Sector | Technology |
| Employees | 2 |
Contact Details
Address: 1185 Avenue of the Americas, Suite 249 New York, New York 10036 United States | |
| Phone | 856 848 8698 |
| Website | tnfpharma.com |
Stock Details
| Ticker Symbol | QCLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001607963 |
| CUSIP Number | 62856X300 |
| ISIN Number | US62856X3008 |
Key Executives
| Name | Position |
|---|---|
| Joshua N. Silverman | Executive Chairman of the Board |
| Ian Rhodes CPA | Chief Financial Officer |
| Dr. Mitchell Glass M.D. | Chief Medical Officer and Director |
| Robert Schatz | Investor Relations Officer |